(NASDAQ: ANIP) Ani Pharmaceuticals's forecast annual revenue growth rate of 5.83% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.13%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.76%.
Ani Pharmaceuticals's revenue in 2024 is $517,460,000.On average, 4 Wall Street analysts forecast ANIP's revenue for 2024 to be $11,192,862,408, with the lowest ANIP revenue forecast at $11,107,042,885, and the highest ANIP revenue forecast at $11,274,193,813. On average, 4 Wall Street analysts forecast ANIP's revenue for 2025 to be $12,085,200,891, with the lowest ANIP revenue forecast at $11,821,366,678, and the highest ANIP revenue forecast at $12,268,920,105.
In 2026, ANIP is forecast to generate $12,832,241,804 in revenue, with the lowest revenue forecast at $12,641,811,386 and the highest revenue forecast at $13,166,543,661.